Health Care

SiNtx insider buying shows confidence: President Ryan’s April 13 purchase signals long‑term belief in the silicon‑nitride platform amid steady price gains.

Julie Rubinstein’s disciplined Rule 10b‑5‑1 trades show Adaptive Biotechnologies’ leadership confidence: buying low at $7.27, selling high near $14, indicating a long‑term equity strategy and alignment with shareholder value.

Investor insight: Vanda Pharmaceuticals’ insider moves show a steady RSU schedule and disciplined buying, confirming management’s confidence in its CNS pipeline.

Lucid Diagnostics insider CMO adds 650k restricted shares, signaling leadership confidence in its esophageal‑cancer diagnostics platform and potential upside.

George Gregory’s bulk purchases of Mesoblast shares signal confidence in its biotech pipeline, especially after FDA approval for Ryoncil, and may anchor the stock during volatile clinical milestones.

Elevance Health insider activity shows board confidence: Aziz Kabeer’s share purchase, high option volume, and Medicare/Medicaid expansion signal long‑term value, yet investors should watch upcoming option expirations for potential dilution.

Insider George Gregory buys 13.5 M Mesoblast shares at $1.48 after FDA green‑light, signaling confidence in DMD therapy and potential upside for risk‑tolerant biotech investors.

Explore how Adaptive Biotechnologies’ chief people officer’s recent buy/sell trades signal insider confidence and strategic liquidity management amid a 63% rally.

Whitehawk CEO’s April share sale is a routine tax‑dump move, not a red flag, as the biotech’s future hinges on clinical milestones, not insider trades.

Sonida Senior Living insider sale: CEO and CFO sell, SVP Tabitha divests 402 shares—small move amid big capital re‑org plans for APAC expansion.